Gregory Martini was named Chief Financial Officer of Kyverna Therapeutics, Inc., effective May 18, 2026. As of November 6, 2026, Kyverna Therapeutics, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on May 18, 2026, naming 2 appointments (Form 8-K, May 18, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Kyverna Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Kyverna Therapeutics, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-05-18. It names 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Kyverna Therapeutics, Inc. files it.
Also on the record for Kyverna Therapeutics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| October 19, 2026 | Stake report, Schedule 13G, by Orin Hirschman | 5.9% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by Bain Capital Life Sciences Opportunities III, LP | 4.75% of the class | 5%+ stakes | Source |
| July 29, 2026 | Stake report, Schedule 13G, by BlackRock, Inc. | 5.1% of the class | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G/A, by Bain Capital Life Sciences Opportunities III, LP | 5.4% of the class | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G/A, by Michael P. Rubin | 6.1% of the class | 5%+ stakes | Source |
| February 6, 2026 | Stake report, Schedule 13G/A, by Dr. Beth C. Seidenberg ("Seidenberg") | 7.8% of the class | 5%+ stakes | Source |
| November 17, 2025 | Stake report, Schedule 13G, by GordonMD Global Investments LP | 7% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Kyverna Therapeutics, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Kyverna Therapeutics, Inc. and the records around it.
Kyverna Therapeutics, Inc. elsewhere on the record
- 5%+ stake filings Oct 2026
- Who owns it
Companies that share a holder
- GordonMD Global Investments LP also filed stake reports on 1 other company: Pyxis Oncology, Inc. (Oct 2026)
- Bain Capital Life Sciences Opportunities III, LP also filed stake reports on 2 other companies: CABALETTA BIO, INC. (Aug 2026), CENTURY THERAPEUTICS, INC. (Nov 2025)
- Westlake BioPartners Fund I, L.P. ("Westlake Fund I") also filed stake reports on 2 other companies: Electra Therapeutics, Inc. (Oct 2026), Latigo Biotherapeutics, Inc. (Oct 2026)
Watch Kyverna Therapeutics, Inc.
Get an email when Kyverna Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Kyverna Therapeutics, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Kyverna Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Kyverna Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
8 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-05-18 | In | Chief Financial Officer | 2026-05-18 | 8-K, 2026-05-18 | |
| 2026-05-18 | In | 8-K, 2026-05-18 |
Who leads Kyverna Therapeutics, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Financial Officer: Gregory Martini, appointed, effective 2026-05-18 (filed 2026-05-18).
New leaders reset buying decisions — get the Full Report on Kyverna Therapeutics, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chief Financial Officer at Kyverna Therapeutics, Inc., with the record behind each one.
Find candidates like Chief Financial Officer at Kyverna Therapeutics, Inc.Every change, in the filing's words
Appointed: Gregory Martini, Chief Financial Officer, effective 2026-05-18
On May 14, 2026, the Board of Directors (the "Board") of Kyverna Therapeutics, Inc. (the "Company") appointed Gregory Martini as the Company's Chief Financial Officer, effective May 18, 2026 (the "Effective Date").
Appointed: Gregory Martini
In this role, Mr. Martini will serve as the Company's principal financial officer and principal accounting officer.
- Mr. Martini, age 38, most recently served as chief financial officer of Ironwood Pharmaceuticals Inc ("Ironwood") from January 2025 to May 2026.
- He previously served as vice president, strategic finance and investor relations of Ironwood from March 2022 to January 2025 and senior director, financial planning and analysis of Ironwood from August 2020 to March 2022.
- Prior thereto, Mr. Martini served in various financial planning and analysis roles of increasing responsibility enterprise-wide at Ironwood, supporting the commercial, research and development, and general and administrative functions.
- Before joining Ironwood in 2017, Mr. Martini served in various financial and corporate development roles at Thermo Fisher Scientific, Ernst & Young LLP and Raytheon Technologies.
- Mr. Martini holds a B.S. in finance from Bentley University.
- In connection with his appointment, on May 8, 2026, Mr. Martini and the Company entered into an offer letter (the "Offer Letter").
- Pursuant to the Offer Letter, Mr. Martini's initial annualized salary will be $525,000 (the "Base Salary").
- His salary and performance bonus percentage may be increased in the future at the discretion of the Compensation Committee of the Board.
- Mr. Martini's employment will be on an "at-will" basis.
Tools for this story
Each opens in a new tab, filled in for Kyverna Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.